PCRX insider filings
Pacira BioSciences, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-17. Screen PCRX transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 16 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 6,000 shares, $217,920 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 92.
- Largest priced transaction: sale of 6,000 shares @ $36.32 ($217,920) by RIKER LAUREN, filed 2026-10-09.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| RIKER LAUREN — Senior Vice President, Finance | 2 | — | 1 leg · 6,000 sh · $217,920 | 15 |
| Brege Laura — Director | 1 | — | — | 12 |
| CHRISTIE CHRISTOPHER — Director | 1 | — | — | 11 |
| Froimson Mark — Director | 1 | — | — | 11 |
| SLONIN JONATHAN — Chief Medical Officer | 1 | — | — | 7 |
| WILLIAMS KRISTEN — Chief Administrative Officer | 1 | — | — | 7 |
| BIGAL MARCELO — Director | 1 | — | — | 6 |
| YANG MICHAEL J. — Director | 1 | — | — | 6 |
| Young Alethia — Director | 1 | — | — | 5 |
| Cross Shawn — Chief Financial Officer | 2 | — | — | 4 |
+4 more insiders in the window, not shown — every filing appears in the table below.
Recent insider filings — Pacira BioSciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4 | SLONIN JONATHAN — Chief Medical Officer | Disposition to issuer (D): 216,729.67 @ $36.50 · Disposition to issuer (D): 35,500 (derivative) · Disposition to issuer (D): 14,137 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 24,800 (derivative) · Disposition to issuer (D): 27,500 (derivative) · +1 more | EDGAR |
| 2026-11-17 | 4 | Brege Laura — Director | Code (U): 23,715 @ $36.50 · Disposition to issuer (D): 6,405 @ $36.50 · Disposition to issuer (D): 2,975 (derivative) · Disposition to issuer (D): 4,693 (derivative) · Disposition to issuer (D): 8,437 (derivative) · Disposition to issuer (D): 8,027 (derivative) · +6 more | EDGAR |
| 2026-11-17 | 4 | RIKER LAUREN — Senior Vice President, Finance | Code (U): 6,881.24 @ $36.50 · Disposition to issuer (D): 55,403 @ $36.50 · Disposition to issuer (D): 6,250 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 6,000 (derivative) · +7 more | EDGAR |
| 2026-11-17 | 4 | WIGGANS THOMAS G — Director | Disposition to issuer (D): 32,675 (derivative) | EDGAR |
| 2026-11-17 | 4 | BIGAL MARCELO — Director | Code (U): 11,393 @ $36.50 · Disposition to issuer (D): 6,405 @ $36.50 · Disposition to issuer (D): 12,179 (derivative) · Disposition to issuer (D): 11,279 (derivative) · Disposition to issuer (D): 10,891 (derivative) · Disposition to issuer (D): 30,967 (derivative) | EDGAR |
| 2026-11-17 | 4 | Froimson Mark — Director | Code (U): 20,136 @ $36.50 · Disposition to issuer (D): 6,405 @ $36.50 · Disposition to issuer (D): 4,693 (derivative) · Disposition to issuer (D): 8,437 (derivative) · Disposition to issuer (D): 8,027 (derivative) · Disposition to issuer (D): 7,626 (derivative) · +5 more | EDGAR |
| 2026-11-17 | 4 | Cross Shawn — Chief Financial Officer | Code (U): 9,210 @ $36.50 · Disposition to issuer (D): 86,591 @ $36.50 · Disposition to issuer (D): 150,000 (derivative) | EDGAR |
| 2026-11-17 | 4 | CHRISTIE CHRISTOPHER — Director | Code (U): 16,654 @ $36.50 · Disposition to issuer (D): 6,405 @ $36.50 · Disposition to issuer (D): 8,027 (derivative) · Disposition to issuer (D): 7,626 (derivative) · Disposition to issuer (D): 8,225 (derivative) · Disposition to issuer (D): 12,179 (derivative) · +5 more | EDGAR |
| 2026-11-17 | 4 | Teehan Brendan — Chief Commercial Officer | Disposition to issuer (D): 100,934.27 @ $36.50 · Disposition to issuer (D): 99,500 (derivative) | EDGAR |
| 2026-11-17 | 4 | WILLIAMS KRISTEN — Chief Administrative Officer | Disposition to issuer (D): 167,062 @ $36.50 · Disposition to issuer (D): 2,953 (derivative) · Disposition to issuer (D): 10,560 (derivative) · Disposition to issuer (D): 19,685 (derivative) · Disposition to issuer (D): 17,500 (derivative) · Disposition to issuer (D): 24,800 (derivative) · +1 more | EDGAR |
| 2026-11-17 | 4 | YANG MICHAEL J. — Director | Code (U): 13,393 @ $36.50 · Disposition to issuer (D): 6,405 @ $36.50 · Disposition to issuer (D): 12,179 (derivative) · Disposition to issuer (D): 11,279 (derivative) · Disposition to issuer (D): 10,891 (derivative) · Disposition to issuer (D): 30,967 (derivative) | EDGAR |
| 2026-11-17 | 4 | Hirawat Samit — Director | Disposition to issuer (D): 6,405 @ $36.50 · Disposition to issuer (D): 10,891 (derivative) · Disposition to issuer (D): 39,291 (derivative) | EDGAR |
| 2026-11-17 | 4 | Young Alethia — Director | Disposition to issuer (D): 17,798 @ $36.50 · Disposition to issuer (D): 12,179 (derivative) · Disposition to issuer (D): 11,279 (derivative) · Disposition to issuer (D): 10,891 (derivative) · Disposition to issuer (D): 30,967 (derivative) | EDGAR |
| 2026-11-17 | 4 | Lee Frank D. — Chief Executive Officer, Director | Disposition to issuer (D): 660,830.84 @ $36.50 · Disposition to issuer (D): 692,512 (derivative) | EDGAR |
| 2026-11-03 | 4 | Cross Shawn — Chief Financial Officer | Tax withholding (F): 9,540 @ $36.39 | EDGAR |
| 2026-10-09 | 4 | RIKER LAUREN — Senior Vice President, Finance | Option exercise (M): 6,000 @ $32.35 · Sale (S): 6,000 @ $36.32 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-08-18 | 4 | SLONIN JONATHAN — Chief Medical Officer | Sale (S): 3,040 @ $23.23 | EDGAR |
| 2026-06-12 | 4 | Hirawat Samit — Director | Grant/award (A): 6,405 @ $0 · Grant/award (A): 10,891 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | RIKER LAUREN — Senior Vice President, Finance | Sale (S): 6,115 @ $23.50 | EDGAR |
| 2026-06-12 | 4 | CHRISTIE CHRISTOPHER — Director | Grant/award (A): 6,405 @ $0 · Grant/award (A): 10,891 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Young Alethia — Director | Grant/award (A): 6,405 @ $0 · Grant/award (A): 10,891 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | YANG MICHAEL J. — Director | Grant/award (A): 6,405 @ $0 · Grant/award (A): 10,891 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | BIGAL MARCELO — Director | Grant/award (A): 6,405 @ $0 · Grant/award (A): 10,891 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Froimson Mark — Director | Grant/award (A): 6,405 @ $0 · Grant/award (A): 10,891 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Brege Laura — Director | Grant/award (A): 6,405 @ $0 · Grant/award (A): 10,891 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | WIGGANS THOMAS G — Director | Grant/award (A): 32,675 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | RIKER LAUREN — Senior Vice President, Finance | Tax withholding (F): 3,187 @ $22.32 | EDGAR |
| 2026-06-05 | 4 | SLONIN JONATHAN — Chief Medical Officer | Tax withholding (F): 4,728 @ $22.32 | EDGAR |
| 2026-06-05 | 4 | WILLIAMS KRISTEN — Chief Administrative Officer | Tax withholding (F): 8,528 @ $22.32 · Sale (S): 10,259 @ $22.27 | EDGAR |
| 2026-04-24 | 4 | Cross Shawn — Chief Financial Officer | Option exercise (M): 12,941 @ $16.45 · Sale (S): 12,941 @ $25.16 · Option exercise (M): 12,941 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Cross Shawn — Chief Financial Officer | Option exercise (M): 7,714 @ $16.45 · Sale (S): 7,714 @ $25.14 · Option exercise (M): 2,845 @ $16.45 · Sale (S): 2,845 @ $25.01 · Option exercise (M): 1,500 @ $16.45 · Sale (S): 1,500 @ $25.01 · +3 more | EDGAR |
| 2026-03-19 | 4 | SLONIN JONATHAN — Chief Medical Officer | Sale (S): 3,261 @ $22.82 | EDGAR |
| 2026-03-19 | 4 | Froimson Mark — Director | Sale (S): 500 @ $21.81 | EDGAR |
| 2026-03-19 | 4/A | Kronenfeld Mark A. — Director | Grant/award (A): 6,163 @ $0 | EDGAR |
| 2026-02-13 | 4 | Cross Shawn — Chief Financial Officer | Grant/award (A): 49,091 @ $0 | EDGAR |
| 2026-02-13 | 4 | Teehan Brendan — Chief Commercial Officer | Grant/award (A): 51,714 @ $0 | EDGAR |
| 2026-02-13 | 4 | RIKER LAUREN — Senior Vice President, Finance | Grant/award (A): 19,273 @ $0 | EDGAR |
| 2026-02-13 | 4 | SLONIN JONATHAN — Chief Medical Officer | Grant/award (A): 54,546 @ $0 | EDGAR |
| 2026-02-13 | 4 | Lee Frank D. — Chief Executive Officer, Director | Grant/award (A): 261,818 @ $0 | EDGAR |
| 2026-02-13 | 4 | WILLIAMS KRISTEN — Chief Administrative Officer | Grant/award (A): 54,546 @ $0 | EDGAR |
| 2026-02-03 | 4 | RIKER LAUREN — Senior Vice President, Finance | Tax withholding (F): 2,751 @ $20.54 · Sale (S): 4,000 @ $20.81 | EDGAR |
| 2026-02-03 | 4 | SLONIN JONATHAN — Chief Medical Officer | Tax withholding (F): 6,168 @ $20.54 | EDGAR |
| 2026-02-03 | 4 | Teehan Brendan — Chief Commercial Officer | Tax withholding (F): 5,182 @ $20.54 | EDGAR |
| 2026-02-03 | 4 | Lee Frank D. — Chief Executive Officer, Director | Tax withholding (F): 41,488 @ $20.54 | EDGAR |
| 2026-02-03 | 4 | WILLIAMS KRISTEN — Chief Administrative Officer | Tax withholding (F): 17,134 @ $20.54 · Sale (S): 13,137 @ $20.53 | EDGAR |
| 2026-01-29 | 4 | Hirawat Samit — Director | Grant/award (A): 39,291 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | SLONIN JONATHAN — Chief Medical Officer | Tax withholding (F): 381 @ $24.46 | EDGAR |
| 2026-01-06 | 4 | RIKER LAUREN — Senior Vice President, Finance | Tax withholding (F): 159 @ $24.46 · Sale (S): 1,416 @ $24.24 | EDGAR |
| 2026-01-06 | 4 | Lee Frank D. — Chief Executive Officer, Director | Tax withholding (F): 9,272 @ $24.46 | EDGAR |
| 2026-01-06 | 4 | Teehan Brendan — Chief Commercial Officer | Grant/award (A): 402.27 @ $10.76 | EDGAR |
Recent 8-K events — Pacira BioSciences, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-05 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
GET https://api.filingpulse.io/v1/insider-trades?ticker=PCRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs